Penetratin-modified Lutein Nanoemulsion Gel for the Treatment of Age-related Macular Degeneration
Overview
Authors
Affiliations
: Lutein is the primary macular pigment with an favorable effect on the treatment of age-related macular degeneration (AMD). However, the poor water solubility of lutein hinders its absorption and delivery. In this study, a penetratin-modified lutein nanoemulsion gel (GEL) was prepared for the treatment of AMD.: A nanoemulsion (NE) was prepared and modified with penetratin (P-NE) to improve the penetration. The effect of penetratin was evaluated by cell uptake and intraocular distribution assays. A dry AMD model was induced using NaIO, and the therapeutic effect was evaluated by electroretinography, the number of apoptosis cells and the reactive oxygen species (ROS) level.: Lutein showed a good ability to protect ARPE-19 from the damage of HO and the uptake rate of P-NE was significantly higher than NE. In the efficacy experiments, the structure of retina was significantly improved after treatment, the apoptosis rate decreased from 31.98% to 2.05%, and the level of ROS was significantly decreased ( < 0.0001).: With the aid of penetratin, lutein could be delivered to the retina effectively. The P-NE GEL could evidently inhibit the apoptosis and ROS, demonstrating that the P-NE GEL has a good application prospect in the treatment of AMD.
Utilization of Nanoparticles for Treating Age-Related Macular Degeneration.
Nikolaidou A, Spyratou E, Sandali A, Gianni T, Platoni K, Lamprogiannis L Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40005976 PMC: 11858808. DOI: 10.3390/ph18020162.
Khan S, Do C, Ho E Drug Deliv Transl Res. 2024; .
PMID: 39674854 DOI: 10.1007/s13346-024-01756-x.
Nutraceuticals for Diabetic Retinopathy: Recent Advances and Novel Delivery Systems.
Ye X, Fung N, Lam W, Lo A Nutrients. 2024; 16(11).
PMID: 38892648 PMC: 11174689. DOI: 10.3390/nu16111715.
Dai Y, Guo Y, Tang W, Chen D, Xue L, Chen Y J Nanobiotechnology. 2024; 22(1):252.
PMID: 38750509 PMC: 11097501. DOI: 10.1186/s12951-024-02501-9.
OCTN2- and ATB-targeted nanoemulsions for improving ocular drug delivery.
Tang B, Wang Q, Zhang G, Zhang A, Zhu L, Zhao R J Nanobiotechnology. 2024; 22(1):130.
PMID: 38532399 PMC: 10964573. DOI: 10.1186/s12951-024-02402-x.